Comprehensive Guide to RNA Capping: Structure, Mechanisms, Functions, and Viral Strategies

Table of Contents

• Introduction to RNA Capping
• Structure of the 5′ Cap
• The Timing of Capping
• Enzymes Involved in Capping
• Mechanism of Cap Synthesis
• Types of RNA Caps (Cap 0, Cap 1, Cap 2)
• Functions of the 5′ Cap
• The Cap-Binding Complex
• Decapping and Turnover
• Viral Capping Strategies
• Conclusions
• References

Introduction to RNA Capping

• RNA capping refers to the addition of a 7-methylguanosine (m7G) structure to the 5′ end of RNA transcripts, which plays a critical role in regulating RNA stability, metabolism, and overall biological function.
• In eukaryotic cells, a methylated guanosine is added co-transcriptionally to the 5′ end of RNA, serving as a distinctive molecular signature that identifies and protects mRNA.
• In bacterial systems, cellular metabolites such as NAD and CoA can function as non-canonical caps, modifying both regulatory small RNAs and messenger RNAs.
• RNA caps exhibit significant chemical diversity across all domains of life, including canonical m7G cap structures, metabolite-derived caps, and various methylated phosphate modifications.

Structure of the 5′ Cap

To regulate the RNA life cycle, both eukaryotes and prokaryotes exhibit a wide variety of 5′ terminal structures.

In Eukaryotes:

• The 5′ cap is a highly regulated structure mainly present on mRNAs transcribed by RNA polymerase II.
• It consists of a guanosine nucleotide methylated at the N7 position (m7G), which imparts a positive charge essential for recognition by nuclear and cytoplasmic cap-binding proteins.
• The m7G is connected to the first nucleotide of the RNA via an unusual reverse 5′–5′ triphosphate linkage (m7GpppN), forming an inverted structure that protects RNA from degradation by 5′–3′ exoribonucleases.
• Small nuclear RNAs (snRNAs) often undergo additional methylation, resulting in a 2,2,7-trimethylguanosine (TMG) cap.
• Certain small RNAs, such as U6, have a simpler cap structure where a methyl group is directly attached to the terminal γ-phosphate of the initiating nucleotide.

In Prokaryotes:

• Unlike eukaryotes, bacteria do not possess the canonical m7G cap and instead use various cellular metabolites as non-canonical caps during transcription initiation.
• Cofactors such as Nicotinamide Adenine Dinucleotide (NAD), Flavin Adenine Dinucleotide (FAD), and 3′-dephospho-Coenzyme A (dpCoA) serve as RNA caps in bacterial systems.
• These metabolites are incorporated via their adenosine moiety, which functions as the initiating nucleotide for RNA synthesis; for instance, in NAD-capped RNA, the nicotinamide riboside is linked to adenosine through a pyrophosphate bond that initiates the RNA chain.
• Bacteria can also utilize uridine-containing sugars like UDP-Glucose (UDP-Glc) and UDP-N-acetylglucosamine (UDP-GlcNAc) as 5′ caps.
• During stress conditions, bacteria incorporate alarmone molecules such as Ap4A or Ap3G (NpnN) at the 5′ end, with their intracellular levels increasing during metabolic changes.
• Several metabolite-derived caps, including NAD, FAD, and UDP-sugars, have also been identified in eukaryotic mRNAs and mitochondrial RNAs, although they occur at much lower abundance compared to the canonical m7G cap.

The Timing of Capping

• It refers to the precise stage during transcription at which the 5′ end of a newly synthesized (nascent) RNA molecule undergoes chemical modification.
• The timing and underlying mechanisms of capping differ markedly between eukaryotes and prokaryotes.

In Eukaryotes

• RNA capping takes place in the nucleus while RNA Polymerase II is actively synthesizing the RNA strand.
• The process is initiated when the nascent RNA transcript reaches a length of approximately 20–30 nucleotides.
• Capping enzymes are recruited to the Serine-5 phosphorylated C-terminal domain (CTD) of RNA Polymerase II, allowing immediate modification of the RNA as it emerges from the polymerase exit channel.
• Certain RNAs, such as processed snoRNAs or stored mRNAs, can undergo recapping in the cytoplasm after prior decapping, functioning as an additional regulatory mechanism.

In Prokaryotes

• In bacterial systems, capping occurs at the very initiation of transcription.
• The bacterial RNA Polymerase directly incorporates a metabolite such as NAD⁺, FAD, or CoA as the initiating nucleotide instead of the standard ATP or GTP.
• As a result, the cap is integrated into the RNA molecule from the very beginning rather than being added post-transcriptionally.
• This process is referred to as the Non-Canonical Initiating Nucleotide (NCIN) mechanism.

Enzymes Involved in Capping

• NA capping is carried out by specialized enzymes that chemically modify the 5′ end of a nascent RNA transcript.
• These enzymes differ between the canonical capping system in eukaryotes and the metabolite-based capping system identified in prokaryotes.

Eukaryotic Capping Enzymes

• Formation of the m7G cap requires a series of coordinated enzymatic steps.
• RNA Triphosphatase (RTPase): This enzyme removes the terminal (γ) phosphate from the 5′ triphosphate end (pppN) of the nascent RNA, converting it into a 5′ diphosphate RNA (ppN).
• RNA Guanylyltransferase (GTase): This enzyme transfers a GMP moiety from GTP to the 5′ diphosphate RNA through a two-step “ping-pong” mechanism that involves a covalent lysyl-GMP intermediate.
• Guanine-N7 Methyltransferase (G-N-7MTase): This enzyme methylates the N7 position of the added guanosine using S-adenosyl-L-methionine (SAM), resulting in the formation of the functional Cap 0 structure.
• In metazoans, additional modification is carried out by ribose methyltransferases (CMTR1 and CMTR2), which methylate the 2′-O position of the first and second nucleotides to generate Cap 1 and Cap 2 structures.
• In mammals and other vertebrates, RTPase and GTase activities are combined into a single bifunctional enzyme known as RNGTT.
• In yeast, these enzymatic functions are performed by distinct proteins: Cet1 (RTPase), Ceg1 (GTase), and Abd1 (N7 methyltransferase).

Prokaryotic Capping Enzymes

• RNA Polymerase (RNAP): In bacteria, RNA polymerase itself functions as the primary capping enzyme by directly incorporating metabolites such as NAD⁺, FAD, or dpCoA in place of standard nucleoside triphosphates during transcription initiation.
• Lysyl-tRNA Synthetase (LysU): This enzyme can attach alarmone caps (dinucleoside polyphosphates such as Ap4A) to 5′ triphosphorylated RNA transcripts, particularly under stress conditions.
• NudC: This enzyme plays a key role in regulating RNA stability by removing NAD⁺ caps from RNA molecules, thereby influencing their turnover.

Mechanism of Cap Synthesis

Eukaryotic Mechanism

• In eukaryotes, synthesis of the 7-methylguanosine (m7G) cap occurs co-transcriptionally through a series of well-coordinated enzymatic steps.
• Terminal Dephosphorylation: RNA triphosphatase (RTPase) removes the terminal (γ) phosphate from the nascent 5′-triphosphorylated RNA (pppRNA), producing a 5′-diphosphorylated RNA (ppRNA) and releasing inorganic phosphate (Pi).
• Guanylylation (GMP Transfer): RNA guanylyltransferase (GTase) catalyzes a two-step “ping-pong” reaction. It first reacts with GTP to form a high-energy covalent lysyl-GMP intermediate, releasing pyrophosphate (PPi). The GMP is then transferred to the 5′ diphosphate RNA end, forming a unique reverse 5′–5′ triphosphate linkage (GpppN).
• N7-Methylation: Guanine-N7 methyltransferase (N7MTase) transfers a methyl group from S-adenosyl-L-methionine (SAM) to the N7 position of the added guanosine, producing the Cap 0 structure (m7GpppN).
• Ribose Methylation: In higher eukaryotes, 2′-O-methyltransferases further methylate the ribose sugars of the first and second nucleotides, generating Cap 1 and Cap 2 structures, respectively.

Prokaryotic Mechanism

• In prokaryotes and some eukaryotic organelles, many non-canonical caps are incorporated at the very beginning of RNA synthesis rather than being added later.
• Transcription Initiation: RNA Polymerase (RNAP) initiates transcription by selecting a non-canonical initiating nucleotide (NCIN), such as NAD⁺, FAD, or dpCoA, instead of a standard ATP or GTP.
• Direct Incorporation: The selected metabolite is incorporated directly into the RNA as part of the first phosphodiester bond, thereby forming the cap structure at the start of transcription.
• Determinants: The efficiency of NCIN incorporation depends on promoter sequence elements and the structural features of the “Rif-pocket” within RNA Polymerase, which stabilizes the metabolite during transcription initiation.

Types of RNA Caps (Cap 0, Cap 1, Cap 2)

• The canonical eukaryotic RNA cap consists of a guanosine methylated at the N7 position (m7G), which is linked to the RNA transcript through an unusual 5′–5′ triphosphate bridge.
• RNA caps are further classified based on additional methylation modifications on the ribose sugars of the first few nucleotides.
• Cap 0 (m7GpppN): Only the terminal guanosine is methylated at the N7 position; this is the predominant cap structure in lower eukaryotes such as yeast and also serves as a precursor for more complex cap forms in higher organisms.
• Cap 1 (m7GpppNm): In addition to the N7 methylation of guanosine, the ribose sugar of the first transcribed nucleotide undergoes 2′-O-methylation; this is the most abundant cap structure in mammals and metazoans and plays an important role in enabling the innate immune system to distinguish host mRNA from viral RNA.
• Cap 2 (m7GpppNmpNm): Along with the modifications seen in Cap 1, the ribose sugar of the second transcribed nucleotide is also 2′-O-methylated; this cap type is commonly found in higher eukaryotes and provides an additional layer of immune recognition and evasion.

Functions of the 5′ Cap

• RNA Stability and Protection: The 5′ cap safeguards mRNA from degradation by 5′–3′ exoribonucleases such as XRN1; transcripts lacking this cap are rapidly directed to cytoplasmic processing bodies (P-bodies) for decay.
• Translation Initiation: The m7G cap is specifically recognized by eIF4E, which facilitates ribosome recruitment to the mRNA. It also promotes mRNA “pseudo-circularization” through interactions between cap-binding proteins and poly(A)-binding proteins, thereby enhancing translation efficiency and processivity.
• Nuclear Export: The cap-binding complex (CBC) identifies the capped RNA within the nucleus and interacts with export factors such as REF/Aly, enabling the transport of mRNA through the nuclear pore complex into the cytoplasm.
• Pre-mRNA Processing: The 5′ cap assists in recruiting the spliceosome, thereby enhancing efficient splicing of the first intron. It also contributes to proper 3′ end formation by stabilizing the cleavage complex at the polyadenylation site.
• Immune Discrimination: Methylation of the first and second nucleotides (Cap 1 and Cap 2) acts as a molecular signature that allows the innate immune system to recognize RNA as “self.” Caps lacking 2′-O-methylation can activate antiviral sensors such as RIG-I and MDA5, leading to interferon production.
• Transcriptional Regulation: Components of the capping machinery, such as the RNMT-RAM complex, can enhance transcription independently of the methylation reaction itself.

The Cap-Binding Complex

• The cap-binding complex (CBC) is a specialized protein assembly that specifically recognizes and binds the 5′ cap structure of RNA.
• It serves as a critical link between newly synthesized RNA transcripts and the cellular machinery responsible for RNA processing, nuclear export, and translation.
• Certain viruses, such as Influenza virus, utilize a unique protein subunit called PB2 to bind and “snatch” host RNA caps, a mechanism distinct from the host CBC.

Eukaryotic Cap-Binding Complex

• The CBC is predominantly localized within the nucleus.
• In mammals, it exists as a heterodimer composed of NCBP2 (CBP20) and NCBP1 (CBP80), where NCBP2 directly binds the methylated guanosine cap in association with NCBP1.
• NCBP2 (CBP20) exhibits high specificity for N7-methylguanosine (m7G), showing over 150-fold greater affinity for m7GpppG compared to unmethylated GpppG.
• It binds co-transcriptionally to the capped RNA and facilitates multiple processes, including splicing of the first intron, stabilization of the 3′ cleavage complex during polyadenylation, and interaction with export factors such as REF/Aly for nuclear export.
• After export to the cytoplasm, the CBC supports the pioneer round of translation, which is crucial for mRNA quality control through nonsense-mediated decay (NMD).
• For ongoing (steady-state) protein synthesis, the CBC is replaced by the eIF4F complex, particularly eIF4E, following the first round of translation.
• An alternative form of the complex can be formed when NCBP3 replaces NCBP2 and associates with NCBP1; this variant plays a specialized role in antiviral defense and clearance of viral infections.

Decapping and Turnover

• Decapping and turnover are regulatory processes in which the 5′ cap of an RNA molecule is enzymatically removed, marking it for rapid degradation.
• This step is essential for controlling mRNA lifespan and enabling cells to respond dynamically to environmental and stress conditions.

Eukaryotic Decapping and Turnover

• The primary enzyme responsible for removing the canonical m7G cap is Dcp2, a member of the Nudix hydrolase family.
• Dcp2 hydrolyzes the 5′–5′ triphosphate bridge, releasing m7GDP and leaving behind a 5′ monophosphate RNA terminus.
• The DXO/Rai1 family removes incomplete or improperly methylated caps, ensuring that defective RNAs do not escape normal decay pathways.
• Metabolite-derived caps such as NAD⁺, FAD, and dpCoA are removed by specialized enzymes including DXO and Nudt12.
• Following decapping, the exposed 5′ monophosphate RNA is rapidly degraded by the 5′–3′ exoribonuclease XRN1, often within cytoplasmic processing bodies (P-bodies).

Prokaryotic Decapping and Turnover

• In bacteria, the phosphohydrolase NudC serves as the primary enzyme for removing NAD-capped RNAs.
• NudC hydrolyzes the pyrophosphate bond of the NAD cap, releasing nicotinamide mononucleotide (NMN).
• The enzyme RppH functions analogously to decapping by converting 5′ triphosphate RNA into a 5′ monophosphate form, thereby marking it for degradation.
• Removal of the cap promotes RNA breakdown either through internal cleavage by RNase E or through processive degradation by RNase J1.
• For stress-induced alarmone caps (NpnN), the enzyme ApaH acts as a decapping factor by hydrolyzing the polyphosphate chain.

Viral Capping Strategies

• Viruses generate 5′ terminal structures that are identical or similar to the host’s canonical m7G cap to protect their RNA from exonucleases and to mimic “self” for efficient translation and immune evasion.
• These strategies vary widely depending on the virus and its genomic organization.

Conventional Viral Capping:

• Many large DNA viruses and some double-stranded RNA (dsRNA) viruses utilize a multi-step enzymatic pathway similar to that of the host cell.
• This pathway involves enzymes such as RNA triphosphatase (RTPase), guanylyltransferase (GTase), and one or more methyltransferases (MTases).
• In viruses like Vaccinia virus, these enzymatic functions are often integrated into a single multifunctional protein complex, such as the D1/D12 heterodimer, which operates as a cap synthesis assembly line.
• Virus families including Poxviridae, Reoviridae, and Mimivirus employ this conventional capping mechanism.

Cap Snatching:

• Segmented negative-strand RNA viruses lack their own capping enzymes and instead “snatch” caps from host mRNAs.
• During this process, the PB2 subunit binds to the 5′ cap of host pre-mRNA, while the PA subunit cleaves the host RNA approximately 10–20 nucleotides downstream.
• The resulting short capped RNA fragment is then used as a primer by the viral RNA-dependent RNA polymerase (PB1) to initiate transcription.
• This mechanism not only provides the virus with a functional cap but also degrades host mRNAs, effectively suppressing host protein synthesis.
• It is a defining strategy of viruses such as Influenza virus and members of Arenaviridae and Bunyaviridae.

Unconventional Synthesis Pathways:

• Some viruses utilize unique enzymatic mechanisms distinct from the classical capping pathway.
• Non-segmented negative-strand viruses such as Vesicular Stomatitis Virus employ a polyribonucleotidyltransferase (PRNTase) activity within their L protein, forming a covalent protein–RNA intermediate and transferring RNA onto GDP to form the cap.
• Alphaviruses such as Chikungunya virus first methylate GTP to form m7GTP, then generate a covalent m7GMP–enzyme intermediate before transferring it to the RNA.
• Coronaviruses, including SARS-CoV-2, use a novel pathway where the NiRAN domain of nsp12 transfers nascent RNA to nsp9 via a phosphoramidate bond before transferring it to GDP.

Non-Canonical Metabolite Capping:

• Some viruses adopt alternative caps derived from cellular metabolites instead of the standard m7G structure.
• Hepatitis C virus can initiate RNA synthesis using FAD as a non-canonical initiating nucleotide, aiding in evasion of host immune sensors such as RIG-I.
• Dengue virus has also been observed to produce RNA transcripts capped with UDP-N-acetylglucosamine.

Cap-Independent Strategies:

• Certain viruses bypass the need for a chemical cap entirely.
• Members of Picornaviridae and Caliciviridae attach a small viral protein called VPg to the 5′ end of their RNA.
• VPg can directly interact with host translation initiation factors such as eIF4E to initiate protein synthesis.
• Some viruses also utilize an Internal Ribosome Entry Site (IRES), a structured RNA element that allows ribosomes to bind and initiate translation independently of the 5′ cap and associated binding proteins.

Conclusions

• RNA capping serves as a defining feature that identifies RNA transcripts and acts as a master regulator of their stability, transport, and overall biological function. The canonical cap consists of a methylated guanosine (m7G) linked via a unique 5′–5′ triphosphate bridge, while non-canonical caps may incorporate cellular metabolites such as NAD⁺ or FAD. Most eukaryotic RNAs acquire this cap co-transcriptionally when the transcript is still very short.
• In contrast, bacteria incorporate metabolite-derived caps directly at the initiation of transcription. Eukaryotes rely on a coordinated set of enzymes—RTPase, GTase, and MTase—to construct the cap, whereas bacteria primarily depend on RNA Polymerase to initiate transcription with a capped structure. Cap synthesis follows a defined sequence involving phosphate removal, guanosine addition via a high-energy intermediate, and subsequent methylation. Cap structures are further categorized based on methylation levels, ranging from Cap 0 in simpler organisms like yeast to Cap 1 and Cap 2 in higher eukaryotes, which help evade immune detection.
• The 5′ cap protects RNA from enzymatic degradation and facilitates the recruitment of translation machinery. Protein complexes such as the cap-binding complex (CBC) and the eIF4F complex, particularly eIF4E, bind to the cap and guide the RNA through processing, export, and translation, ensuring efficient protein synthesis.
• Removal of the cap triggers rapid RNA degradation, thereby regulating RNA lifespan and maintaining cellular homeostasis. This controlled turnover is essential for proper gene expression and adaptation to cellular conditions.
• Viruses exploit diverse strategies to maintain efficient gene expression, including encoding their own capping enzymes, hijacking host caps through cap-snatching mechanisms, or utilizing alternative strategies such as protein-linked caps to mimic cap function and evade host defenses.

References

• Boivin S, Cusack S, Ruigrok RWH, Hart DJ. (2010). Structural insights into Influenza A virus polymerase and its role in replication and host adaptation. Journal of Biological Chemistry, 285(37): 28411–28417.
• Cahová H, Winz ML, Höfer K, Nübel G, Jäschke A. (2015). Identification of NAD as a bacterial RNA cap using captureSeq technology. Nature, 519(7543): 374–377.
• Chen Y, Guo D. (2016). Mechanistic overview of RNA capping and methylation in coronavirus. Virologica Sinica, 31(1): 3–11.
• Decroly E, Canard B. (2017). Biochemical basis and inhibition strategies targeting viral RNA capping pathways. Current Opinion in Virology, 24: 87–96.
• Decroly E, Ferron F, Lescar J, Canard B. (2012). Overview of conventional and alternative mechanisms of viral mRNA capping. Nature Reviews Microbiology, 10(1): 51–65.
• Doamekpor SK, Sharma S, Kiledjian M, Tong L. (2022). Advances in understanding non-canonical RNA capping and decapping processes. Journal of Biological Chemistry, 298(8).
• Galloway A, Cowling VH. (2019). Regulation of mRNA capping and its impact on mammalian cell function and fate. Biochimica et Biophysica Acta – Gene Regulatory Mechanisms, 1862(3): 270–279.
• Jiao X, Doamekpor SK, Bird JG, Nickels BE, Tong L, Hart RP, Kiledjian M. (2017). Role of NAD-capped RNA in promoting decay via DXO-mediated deNADding in human cells. Cell, 168(6): 1015–1027.e10.
• Li J, Zhang Y. (2012). Mechanisms of mRNA cap methylation in Vesicular Stomatitis Virus. In: Methylation – From DNA, RNA and Histones to Diseases and Treatment. InTech.
• Navas LE, Carnero A. (2021). Functional links between NAD⁺ metabolism, immune response, stemness, and cancer biology. Signal Transduction and Targeted Therapy, 6(1).
• Park GJ, Osinski A, Hernandez G, et al. (2022). Mechanistic insights into RNA capping by SARS-CoV-2. Nature, 609(7928): 793–800.
• Ramanathan A, Robb GB, Chan SH. (2016). Biological roles and applications of mRNA capping. Nucleic Acids Research, 44(16): 7511–7526.
• Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. (2014). RNA synthesis, capping, and proofreading mechanisms in SARS coronavirus. Virus Research, 194: 90–99.
• Teale FWJ. (2025). Emerging roles of flavin adenine dinucleotide (FAD) as a non-canonical RNA cap. Archives of Biochemistry and Biophysics, 766(2): 110326.
• Wang J, Chew BL, Lai Y, et al. (2019). Profiling the RNA cap epitranscriptome reveals diverse cap structures in cellular and viral RNAs. Nucleic Acids Research, 47(20).